2289 Stock Overview
Engages in the pharmaceutical distribution business in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Charmacy Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.35 |
| 52 Week High | HK$16.50 |
| 52 Week Low | HK$6.81 |
| Beta | -0.46 |
| 11 Month Change | 1.46% |
| 3 Month Change | -3.02% |
| 1 Year Change | -33.20% |
| 33 Year Change | 22.79% |
| 5 Year Change | 15.97% |
| Change since IPO | 4.38% |
Recent News & Updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29Shareholder Returns
| 2289 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 1.8% | -4.6% | -4.3% |
| 1Y | -33.2% | -37.8% | -2.8% |
Return vs Industry: 2289 exceeded the Hong Kong Healthcare industry which returned -37.8% over the past year.
Return vs Market: 2289 underperformed the Hong Kong Market which returned -2.8% over the past year.
Price Volatility
| 2289 volatility | |
|---|---|
| 2289 Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.2% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2289 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2289's weekly volatility has decreased from 11% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 834 | Chuanglong Yao | www.chmyy.com |
Charmacy Pharmaceutical Co., Ltd. engages in the pharmaceutical distribution business in the People’s Republic of China. The company distributes western medicines, Chinese patent medicines, healthcare products, and related pharmaceutical products consulting services to downstream distributors and retail terminals. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online, make inquires and payments, etc. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd.
Charmacy Pharmaceutical Co., Ltd. Fundamentals Summary
| 2289 fundamental statistics | |
|---|---|
| Market cap | HK$901.80m |
| Earnings (TTM) | HK$56.67m |
| Revenue (TTM) | HK$4.91b |
15.9x
P/E Ratio0.2x
P/S RatioIs 2289 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2289 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.48b |
| Cost of Revenue | CN¥4.17b |
| Gross Profit | CN¥315.22m |
| Other Expenses | CN¥263.48m |
| Earnings | CN¥51.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 7.03% |
| Net Profit Margin | 1.15% |
| Debt/Equity Ratio | 134.6% |
How did 2289 perform over the long term?
See historical performance and comparison